A practical reference on RP-HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
While the prevalent explanation for osmolyte action relies on excluded volume effects that are entropic in nature, circular dichroism (CD) experiments have shown osmolyte to act through an enthalpic effect. The molecular mechanism for their role in protein stabilization is still not well established, though several mechanisms have been proposed. Computer molecular dynamics simulations suggest that osmolytes stabilize proteins by modifying the hydrogen bonds in the protein hydration layer. Several studies have shown that hydrogen bonds play an important role for the stability between subunits in multimeric proteins. For example, a study of sorbitol dehydrogenase displayed an important hydrogen bonding network which stabilizes the tetrameric quaternary structure within the mammalian sorbitol dehydrogenase protein family. A protein backbone hydrogen bond incompletely shielded from water attack is a dehydron. Dehydrons promote the removal of water through proteins or ligand binding. The exogenous dehydration enhances the electrostatic interaction between the amide and carbonyl groups by de-shielding their partial charges. Furthermore, the dehydration stabilizes the hydrogen bond by destabilizing the nonbonded state consisting of dehydrated isolated charges. Wool, being a protein fibre, is held together by hydrogen bonds, causing wool to recoil when stretched. However, washing at high temperatures can permanently break the hydrogen bonds and a garment may permanently lose its shape.
The company is working with food supplier Warabeya Nichiyo, which already supplies 7-Eleven's commissary food offerings in Japan, to create a US supply chain that will bring higher-quality Western and Japanese food offerings to 7-Eleven stores. Isaka also announced 7-Eleven's plan to grow its footprint and consolidate a larger portion of the US convenience store market. The company announced plans to add hot and cold food options and a larger baked goods selection at up to 1,600 Speedway and Stripes stores. Fuel In the U.S., many 7-Eleven filling stations had gasoline distributed by Citgo, which in 1983 were purchased by Southland Corporation. 50% of Citgo was sold in 1986 to Petróleos de Venezuela, S.A., and the remaining 50% was acquired in 1990. Although Citgo was the predominant partner of 7-Eleven, other oil companies are also co-branded with 7-Eleven, including Fina, Exxon, Mobil, Gulf, Marathon, BP, Amoco, Phillips 66, Conoco, 76, Shell, Chevron (some former TETCO convenience stores were co-branded with Chevron, and Texaco prior to the 7-Eleven purchase in late 2012), Sunoco, and Sinclair. Conoco is the largest 7-Eleven licensee in North America. The Pittsburgh market alone—where 7-Eleven is the market leader by store count but third behind Sheetz and GetGo in revenue— offers fuel from Exxon, Gulf, Marathon (both legacy 7-Eleven locations and Speedway), BP, and Sunoco (the latter two being from 7-Eleven's acquisitions of their company-owned-and-operated locations in the area) and also having previously offered Citgo and Pennzoil at some locations.
== Construction == A Neolithic trackway once ran across what archaeologists have termed the "Flag Fen Basin", from a dry-land area known as Fengate to a natural clay island called Northey. The basin is an embayment of low-lying land on the western margins of the Fens. The level of inundation by 1300 BC led the occupants to construct a timber causeway along the trackway route. The causeway and centre platform were formed by driving 'thousands of posts with long pencil-like tips' through the 'accumulating peaty muds' and into the firmer ground below. The resulting structure covered three and a half acres (1.4 ha). Dendrochronological analysis (dating of the posts by studying tree rings) led to an estimated date for the various stages of construction of between 1365 and 967 BC. Some of the timbers, such as oak, were not native to the local environment. They made a significant effort to transport the timbers to the site from distant sources.
Any single cycle is longer than 90 days, as long as the individual is at least one year post menarche. The cycle is generally shorter than 21 days or longer than 45 days, as long as the individual is at least one year post menarche. The cycle is generally longer than 35 days, as long as the individual is at least three years post menarche. Amenorrhea which is not due to another underlying cause, as long as the individual is at least 15 years old or at least 3 years post thelarche. Biochemical androgen excess in PMOS is assessed using total and free testosterone. Accurate measurement requires tandem mass spectrometry assays, as direct free testosterone tests are not reliable. Interpretation is based on laboratory reference ranges. Hormonal contraception can interfere with hormone levels, so a withdrawal period of at least three months with alternative contraception may be needed. Severely elevated androgen levels may indicate other conditions.
Sources: en.wikipedia.org
In August 1988, the FDA approved minoxidil for treating baldness in men under the brand name "Rogaine" (FDA rejected Upjohn's first choice, Regain, as misleading). The agency concluded that although "the product will not work for everyone", 39% of the men studied had "moderate to dense hair growth on the crown of the head". "Men's Rogaine", marketed by Johnson & Johnson went off-patent on January 20, 2006. In 1991, Upjohn made the product available for women. "Women's Rogaine", marketed by Johnson & Johnson, went off-patent in February 2014.
Another explanation is that the word hoagie arose in the late 19th to early 20th centuries, among the Italian community in South Philadelphia; at the time "on the hoke" meant that someone was destitute. Deli owners gave away scraps of cheeses and meats in an Italian bread-roll known as a "hokie", but Italian immigrants pronounced it "hoagie". Yet another possible origin of the term, as conveyed by Sociology professor Howard Robboy, is that a man in Philadelphia, Alphonso DePalma, who later opened a sandwich shop there, claimed to have said in 1928, "You have to be a hog to eat one of those." DePalma styled himself as "King of the Hoggies" (and eventually "Hoagies") and at one time had several "hoggie" shops around the city. Shortly after World War II, there were numerous varieties of the term in use throughout Philadelphia. By the 1940s, the spelling "hoagie" dominated less-used variations like "hoogie" and "hoggie". By 1955, restaurants throughout the area were using the term hoagie. Listings in Pittsburgh show hoagies arriving in 1961 and becoming widespread in that city by 1966. Former Philadelphia mayor (and later Pennsylvania governor) Ed Rendell declared the hoagie to be the "Official Sandwich of Philadelphia". However, there are claims that the hoagie was actually a product of nearby Chester, Pennsylvania. DiCostanza's in Boothwyn, Pennsylvania claims that the mother of DiConstanza's owner originated the hoagie in 1925 in Chester.
== Open housing movement == In 1948, Shelley v. Kraemer and three other United States Supreme Court cases established that state enforcement of racially restrictive covenants was unconstitutional. This decision revitalized the advocacy for integrated neighborhoods. Suburbs around Detroit expanded dramatically as wealthy African-Americans moved into white neighborhoods. The singular asset that many white residents held after World War II was their home, and they feared that if Black people moved in, the value of their homes would plummet. This fear was preyed upon by blockbusting real estate agents who would manipulate Whites into selling their homes for cheap prices by convincing them that African-Americans were infiltrating the neighborhood. They would even send Black children to go door to door with pamphlets that read, "Now is the best time to sell your house—you know that." With the means to pick up and leave, many white residents fled to the surrounding suburbs. This "white flight" took much away from the city: residents, the middle class, and tax revenues which kept up public services such as schools, police, and parks. Blockbusting agents then profited by reselling these houses at incredibly marked-up prices to African-Americans desperate to get out of the inner city. These inflated prices were only affordable by the black "elite". As wealthier black Detroiters moved into the previously white neighborhoods, they left behind low-income residents in the most inadequate houses at the highest rental.
Sources: en.wikipedia.org
Cohen (1955): working class teenagers joined gangs due to frustration of inability to achieve status and goals of the middle class; Cloward and Ohlin (1960): blocked opportunity, but unequal distribution of opportunities lead to creating different types of gangs (that is, some focused on robbery and property theft, some on fighting and conflict and some were retreatists focusing on drug taking); Spergel (1966) was one of the first criminologists to focus on evidence-based practice rather than intuition into gang life and culture. Participation in gang-related events during adolescence perpetuate a pattern of maltreatment on their own children years later. Klein (1971) like Spergel studied the effects on members of social workers' interventions. More interventions actually lead to greater gang participation and solidarity and bonds between members. Downes and Rock (1988) on Parker's analysis: strain theory applies, labeling theory (from experience with police and courts), control theory (involvement in trouble from early childhood and the eventual decision that the costs outweigh the benefits) and conflict theories. No ethnic group is more disposed to gang involvement than another, rather it is the status of being marginalized, alienated or rejected that makes some groups more vulnerable to gang formation, and this would also be accounted for in the effect of social exclusion, especially in terms of recruitment and retention. These may also be defined by age (typically youth) or peer group influences, and the permanence or consistency of their criminal activity.
Despite these promising findings, translation into clinical applications in humans remains limited, and further research is required to evaluate the safety, efficacy, and feasibility of therapeutic strategies inspired by this model.
In October 2013, A&W opened its first new concept restaurant, A&W Burgers Chicken Floats. The new concept focuses on fresh made-to-order food and heavily emphasizes customer service. The menu features burgers made with fresh beef and a choice of toppings, hand-breaded chicken tenders, all-beef hot dogs, and several sides. The new management gave A&W a significant boost in the number of locations, with 2017 scheduled to have more openings than closures. For 2018, A&W projected an increase in its franchising operations and opening new restaurants. In April 2019, A&W returned to Singapore after a 16-year absence, its first location being at Jewel Changi Airport. In June 2019, the A&W chain started moving its headquarters to the University of Kentucky Coldstream Research Campus in 2019. A&W announced in March 2022 that it was going to withdraw from the Thai market due to economic losses. The restaurants shut down on March 20. A franchise was given to western New York in early 2023, with three locations, the first of which in Niagara Falls, set to open between May and June of that year. There are nearly 1,000 A&W Restaurants worldwide that are owned or franchised through A Great American Brand, with approximately 475 of these restaurants located in the U.S. as of October 2024. A&W rebounded its profits in the first half of 2024, emphasis on its growth is given mainly to single-brand restaurants, as well as restaurants in less conventional locations. In November 2024, the chain announced its entrance to the Milwaukee and Madison markets in Wisconsin.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.